SG11201902940RA - Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same - Google Patents
Bacterial minicells for delivering nucleic acid adjuvants and methods of using the sameInfo
- Publication number
- SG11201902940RA SG11201902940RA SG11201902940RA SG11201902940RA SG11201902940RA SG 11201902940R A SG11201902940R A SG 11201902940RA SG 11201902940R A SG11201902940R A SG 11201902940RA SG 11201902940R A SG11201902940R A SG 11201902940RA SG 11201902940R A SG11201902940R A SG 11201902940RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- adjuvants
- engeneic
- sirius
- pty
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 5
- 102000039446 nucleic acids Human genes 0.000 title abstract 5
- 108020004707 nucleic acids Proteins 0.000 title abstract 5
- 150000007523 nucleic acids Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 230000001580 bacterial effect Effects 0.000 title abstract 2
- 238000012384 transportation and delivery Methods 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 108060000255 AIM2 Proteins 0.000 abstract 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 abstract 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 208000034423 Delivery Diseases 0.000 abstract 1
- 102100024064 Interferon-inducible protein AIM2 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 108091007930 cytoplasmic receptors Proteins 0.000 abstract 1
- 210000000172 cytosol Anatomy 0.000 abstract 1
- 210000001163 endosome Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662405074P | 2016-10-06 | 2016-10-06 | |
| PCT/IB2017/056131 WO2018065923A1 (en) | 2016-10-06 | 2017-10-04 | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201902940RA true SG11201902940RA (en) | 2019-05-30 |
Family
ID=61829954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201902940RA SG11201902940RA (en) | 2016-10-06 | 2017-10-04 | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11485976B2 (zh) |
| EP (1) | EP3522935A4 (zh) |
| JP (2) | JP7213798B2 (zh) |
| CN (1) | CN110022905B (zh) |
| AU (1) | AU2017339841A1 (zh) |
| CA (1) | CA3039010A1 (zh) |
| EA (1) | EA201990689A1 (zh) |
| IL (1) | IL265855B1 (zh) |
| MA (1) | MA46469A (zh) |
| SG (1) | SG11201902940RA (zh) |
| TW (1) | TWI840322B (zh) |
| WO (1) | WO2018065923A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201702627UA (en) * | 2014-10-03 | 2017-04-27 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| EP3826654A4 (en) * | 2018-07-23 | 2022-07-06 | EnGeneIC Molecular Delivery Pty Ltd | BACTERIA-DERIVED MINICELL COMPOSITIONS AND METHODS OF USE THEREOF |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
| JP2001501834A (ja) | 1997-03-19 | 2001-02-13 | ザイモジェネティクス，インコーポレイティド | 分泌される唾液ｚｓｉｇ３２ポリペプチド |
| CN1367701A (zh) | 1999-05-11 | 2002-09-04 | 奥索－麦克尼尔药物公司 | 红细胞生成素给药的药代动力学和药效模型 |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| CN102172406B (zh) | 2001-10-15 | 2013-03-13 | 恩吉尼克分子传递私人有限公司 | 用作体外和体内dna转染与基因治疗载体的完整微细胞 |
| NZ573064A (en) * | 2002-04-04 | 2011-02-25 | Coley Pharm Gmbh | Immunostimulatory G,U-containing oligoribonucleotides |
| CA2511538C (en) * | 2002-12-30 | 2013-11-26 | 3M Innovative Properties Company | Immunostimulatory combinations |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| JP4332558B2 (ja) | 2003-12-09 | 2009-09-16 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 細菌由来のインタクトなミニ細胞を介した非食作用性哺乳動物細胞への標的化遺伝子送達 |
| US8772013B2 (en) * | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| PT1718338E (pt) | 2004-02-02 | 2015-09-21 | Engeneic Molecular Delivery Pty Ltd | Composições e métodos de libertação direcionada de fármacos in vitro e in vivo por meio de minicélulas intactas derivadas de bactérias |
| CN102921019B (zh) * | 2004-08-26 | 2015-04-01 | 恩杰内克分子递送有限公司 | 通过细菌性来源的完整小细胞向哺乳动物细胞递送功能性核酸 |
| CA2658058C (en) | 2006-06-23 | 2016-08-23 | Engeneic Molecular Delivery Pty Ltd. | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| SG10201804257RA (en) * | 2007-03-30 | 2018-06-28 | Engeneic Molecular Delivery Pty Ltd Au | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
| US8492358B2 (en) * | 2010-06-25 | 2013-07-23 | Idera Pharmaceuticals, Inc. | Agonists of toll-like receptor 3 and methods of their use |
| JP5871212B2 (ja) * | 2010-07-28 | 2016-03-01 | 国立大学法人北海道大学 | アジュバント活性を有する新規核酸およびその利用 |
| EP2675474B1 (en) * | 2011-02-15 | 2019-01-16 | Vaxiion Therapeutics, LLC | Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
| JP6538031B2 (ja) | 2013-10-04 | 2019-07-03 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療 |
-
2017
- 2017-10-04 EA EA201990689A patent/EA201990689A1/ru unknown
- 2017-10-04 WO PCT/IB2017/056131 patent/WO2018065923A1/en unknown
- 2017-10-04 CN CN201780073718.5A patent/CN110022905B/zh active Active
- 2017-10-04 IL IL265855A patent/IL265855B1/en unknown
- 2017-10-04 MA MA046469A patent/MA46469A/fr unknown
- 2017-10-04 AU AU2017339841A patent/AU2017339841A1/en active Pending
- 2017-10-04 US US15/725,008 patent/US11485976B2/en active Active
- 2017-10-04 SG SG11201902940RA patent/SG11201902940RA/en unknown
- 2017-10-04 EP EP17857944.7A patent/EP3522935A4/en active Pending
- 2017-10-04 JP JP2019518509A patent/JP7213798B2/ja active Active
- 2017-10-04 CA CA3039010A patent/CA3039010A1/en active Pending
- 2017-10-06 TW TW106134539A patent/TWI840322B/zh active
-
2022
- 2022-11-30 JP JP2022190928A patent/JP2023022207A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA46469A (fr) | 2019-08-14 |
| JP7213798B2 (ja) | 2023-01-27 |
| EA201990689A1 (ru) | 2019-10-31 |
| WO2018065923A1 (en) | 2018-04-12 |
| CN110022905A (zh) | 2019-07-16 |
| TWI840322B (zh) | 2024-05-01 |
| CA3039010A1 (en) | 2018-04-12 |
| IL265855A (en) | 2019-06-30 |
| IL265855B1 (en) | 2024-08-01 |
| AU2017339841A1 (en) | 2019-05-02 |
| CN110022905B (zh) | 2024-02-06 |
| JP2023022207A (ja) | 2023-02-14 |
| EP3522935A1 (en) | 2019-08-14 |
| JP2019533663A (ja) | 2019-11-21 |
| TW201828994A (zh) | 2018-08-16 |
| EP3522935A4 (en) | 2020-05-13 |
| US11485976B2 (en) | 2022-11-01 |
| US20180100159A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201803728YA (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201808619QA (en) | Nucleic acid-polypeptide compositions and uses thereof | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201805217XA (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201810023QA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| SG11201807548SA (en) | Inducible binding proteins and methods of use | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201903737PA (en) | Neutralizing anti-tl1a monoclonal antibodies | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201807134RA (en) | Transposon system and methods of use |